Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme

Completed · Phase 2

Conditions studied: Glioblastoma Multiforme

In brief

This, international, multi-center, Phase 2 study of verubulin will be conducted in patients with newly diagnosed Glioblastoma Multiforme (GBM). The study will be conducted in two parts. Part A is an open-label dose finding study that will determine the safety and tolerability of verubulin in combination with standard treatment. Part B is a randomized open-label study that will investigate progression-free survival and overall survival of patients receiving verubulin, at the dose determined in Part A, in combination with standard treatment versus standard treatment alone.

Key facts

Study ID

NCT01285414

Run by

Myrexis Inc.

People needed

5

Starts

2010-12-01

Expected to finish

2012-03-01

Last updated by the study team

2012-04-11

Who can join

Age: 18 and older, up to 69. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have histologically proven, newly diagnosed glioblastoma multiforme
• Age ≥ 18 years and < 70 years
• Have an ECOG performance score of 0, 1, or 2, or KPS ≥ 70
• Have adequate bone marrow function , liver function, and kidney function before starting therapy
• Begin study therapy no more than 6 weeks after surgery or biopsy
• Subjects that have had surgery must have an MRI ≤ 72 hours after surgery

You may not qualify if…

• Have a carmustine implant (e.g., Gliadel® Wafer)
• Have uncontrolled hypertension (SBP > 140 mmHg or DBP > 90 mmHg for more than 1 week)
• Have a left ventricular ejection fraction below the lower limit of the reference range for the institution, as measured by multiple gated acquisition (MUGA) or echocardiogram (ECHO)
• Have Troponin-I or Troponin T at Screening visit elevated above the upper limit of the reference range of the local institution
• Have an increasing steroid requirement, indicative of a rapidly progressive disease
• Have evidence of new, active intra tumor hemorrhage ≥ CTCAE Grade 2
• Have had prior cranial radiotherapy
• Have history of stroke and/or transient ischemic attack within 2 years of screening
• Have history of cardiovascular disease (e.g., angina, myocardial infarction, congestive heart failure, etc.) within 2 years of screening
• Be pregnant or breast feeding
• Have a history of hypersensitivity reaction to Cremophor® EL
• Have a history of hypersensitivity reaction or intolerance to temozolomide or dacarbazine (DTIC)

Where it is running

• Stanford University — Stanford, California, United States
• University of Texas Health Science Center at Houston — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.